FDA Grants Breakthrough Therapy Designation to Roche's Lung Cancer Immunotherapy

… (Programmed Death-Ligand 1) non-small cell lung cancer (NSCLC) whose disease has progressed … EGFR mutation-positive or ALK-positive tumour). “Lung cancer is the leading cause of … for MPDL3280A in non-small cell lung cancer,’’ said Sandra Horning, MD, Roche …